Marizomib
- Generic Name
- Marizomib
- Drug Type
- Small Molecule
- Chemical Formula
- C15H20ClNO4
- CAS Number
- 437742-34-2
- Unique Ingredient Identifier
- 703P9YDP7F
- Background
Marizomib has been used in trials studying the treatment of Cancer, Melanoma, Lymphoma, Glioblastoma, and Malignant Glioma, among others.
Marizomib Central Nervous System (CNS)
- Conditions
- Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma, Refractory
- Interventions
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT05050305
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Expanded Access for Marizomib
- Conditions
- Solid Tumor
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- Celgene
- Registration Number
- NCT04644107
- Locations
- 🇺🇸
Bristol Myers Squibb, Summit, New Jersey, United States
Phase I Study of Marizomib + Panobinostat for Children With DIPG
- Conditions
- Diffuse Intrinsic Pontine GliomaPediatric Brainstem GliomaPediatric Brainstem Gliosarcoma, RecurrentPediatric CancerPediatric Brain TumorDiffuse Glioma
- Interventions
- First Posted Date
- 2020-04-10
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 4
- Registration Number
- NCT04341311
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma
- First Posted Date
- 2018-11-01
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 4
- Registration Number
- NCT03727841
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma
- Conditions
- High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma
- Interventions
- Drug: nab-sirolimusDrug: nab-sirolimus + bevacizumab
- First Posted Date
- 2018-03-13
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Aadi Bioscience, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT03463265
- Locations
- 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸St. Joseph Heritage Healthcare, Fullerton, California, United States
🇺🇸John Wayne Cancer Institute, Santa Monica, California, United States
A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma
- Conditions
- Newly Diagnosed Glioblastoma
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2024-07-12
- Target Recruit Count
- 749
- Registration Number
- NCT03345095
- Locations
- 🇺🇸
University of California, San Francisco, California, United States
🇨🇦Saint John Regional Hospital, Saint John, New Brunswick, Canada
🇨🇭University Hospital of Geneva, Geneva, Switzerland
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma in RelapseRefractory Multiple MyelomaMultiple Myeloma
- Interventions
- First Posted Date
- 2014-04-03
- Last Posted Date
- 2017-11-22
- Lead Sponsor
- Celgene
- Target Recruit Count
- 38
- Registration Number
- NCT02103335
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Karmanos Cancer Center, Detroit, Michigan, United States
Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma
- First Posted Date
- 2006-11-08
- Last Posted Date
- 2017-11-22
- Lead Sponsor
- Celgene
- Target Recruit Count
- 51
- Registration Number
- NCT00396864
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Univ. of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Premiere Oncology of America, Scottsdale, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.